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Adverse events associated with 
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meta-analysis
Luke e. Grzeskowiak  1,2*, Billy tao3, Emma Knight4, Sarah cohen-Woods5,6 & 
timothy chataway7
While peanut oral immunotherapy (poit) represents a promising treatment for peanut allergies in 
children, safety concerns remain a common barrier to widespread adoption. We aimed to systematically 
assess available evidence to determine the risk and frequency of adverse events occurring during POIT, 
and examine study-level characteristics associated with their occurrence and severity. A systematic 
search of MEDLINE, EMBASE, and Web of Science was conducted through April 2019. Controlled and 
non-controlled studies evaluating POIT were eligible. Twenty-seven studies, involving 1488 subjects, 
were included. Adverse events to POIT were common and led to treatment discontinuation in 6.6% of 
children (95% CI 4.4–9.0; 27 studies, I2 = 48.7%). Adverse events requiring treatment with epinephrine 
occurred among 7.6% (4.5–11.4; 26 studies, I2 = 75.5%) of participants, at a rate of 2.0 per 10,000 doses 
(0.8–3.7; 15 studies, I2 = 64.4). Use of a rush treatment phase and targeting a higher maintenance 
dose were associated with a higher risk and frequency of epinephrine use, while using co-treatments in 
addition to poit was associated with a lower risk of treatment discontinuation due to adverse events. 
While adverse events to POIT are common, this study provides promising explorative evidence that 
certain modifications to existing treatment protocols could significantly improve treatment outcomes.
Peanut allergy is the leading cause of food-related allergic reactions for children in Western countries, affecting 
1–3% of children1–5. While a small percentage of children grow out of their peanut allergy, the only currently 
recognised and supported treatment approach is allergen-avoidance and use of rescue medications for managing 
allergic reactions6. Avoidance, however, can be difficult because peanuts are widely present in many foods, and 
there is also the risk of contamination during manufacturing processes. In addition, labelling can be inadequate 
or misinterpreted by families and caregivers7. As such, accidental ingestion leading to reactions are common even 
under supposedly strict avoidance8–10, representing a significant burden on children and their families11.
As such, there has been significant interest in developing approaches towards the prevention and treatment of 
peanut allergies. Oral immunotherapy (OIT) has recently emerged as an effective treatment in desensitising chil-
dren with a variety of food allergies. While recent systematic reviews have demonstrated the effectiveness of POIT 
in achieving the immunological goal of desensitisation to peanut allergy, they have raised significant concerns 
regarding potential risks associated with treatment12,13. This has led to caution regarding the adoption of POIT 
in clinical practice outside of the trial setting. These previous reviews, however, were restricted to randomised 
controlled trials, omitting a large body of evidence from non-controlled studies that can provide greater evidence 
surrounding likely real-world outcomes associated with POIT in children. In light of this, we sought to quantify 
the risk of adverse events occurring during POIT for peanut allergy in allergic children, and examine study and 
patient level characteristics associated with their occurrence.
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Methods
Search methods and study selection. This systematic review and meta-analysis was performed in 
accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines 
(S1 Table)14. We searched three electronic databases from inception to 9th April 2019: Ovid MEDLINE, EMBASE, 
and Web of Science. Medical subject headings (e.g. MeSH headings) and free word combinations using Boolean 
logic of the following search items were used: ‘peanut’ AND ‘immunotherapy’ (S1 Appendix). Previous reviews, 
bibliographies of published trials, and cross references were also searched. No language restrictions were applied.
Study selection. Eligible studies included prospective controlled or non-controlled studies involving the 
administration of POIT in children less than 18 years of age that reported on safety and/or efficacy outcomes. 
Studies were not eligible for inclusion if they were only published in abstract form. Two independent reviewers 
(LG and BT) screened the titles and abstracts of identified studies. Disagreements were resolved through consen-
sus or consultation with a third independent reviewer (TC).
Data extraction and outcomes of interest. Two reviewers (LG and BT) utilized a standardized data 
extraction sheet to independently extract the following data: study characteristics, patient characteristics, and 
treatment outcome measures. Disagreements were resolved through consensus or consultation with a third inde-
pendent reviewer (TC). We did not contact the authors of eligible studies for additional data.
The primary outcome was adverse events resulting in treatment discontinuation. Secondary outcomes 
included: adverse events requiring any treatment, adverse events requiring treatment with epinephrine, ability 
to reach target maintenance dose, and passing supervised oral food challenge following OIT. For the outcome of 
passing supervised oral food challenge, this had to occur immediately post-intervention. Studies where the super-
vised oral food challenge only occurred following a period of treatment discontinuation (i.e. to evaluate sustained 
unresponsiveness) did not contribute data to this outcome analysis. Where available, we extracted outcomes on 
adverse events occurring during each treatment phase including: rush, build-up, or maintenance. Study quality 
was not formally evaluated due to an absence of validated tools for evaluating risk of bias in the context of this 
type of systematic review. However, as a key marker of study quality and identified source of potential reporting 
bias, for all outcomes we stratified studies according to whether subjects were blinded to POIT or not.
Data analysis. Each outcome was analysed according to intention-to-treat (ITT). For dichotomous out-
comes (e.g. treatment discontinuation) we utilised the total number of subjects who initially received the inter-
vention as the denominator. For outcomes that could occur more than once in the same patient (e.g. number of 
adverse events) we utilised the total number of doses received as the denominator. Binary outcome data were first 
transformed via the Freeman-Tukey double arcsine transformation (and then back transformed where possible 
to show estimates and confidence intervals as percentages), ensuring studies reporting percentages of 0 or 100% 
were included in the meta-analysis15. Transformations also ensured that reported pooled proportions did not fall 
outside of the valid range (0 to 100%). We pooled summary measures using the ‘metaprop_one’ package in STATA 
14 (StataCorp LP, College Station, TX) with 95% confidence intervals calculated using the Wilson method16. 
Univariate meta-regressions of the effects of continuous study-level factors at baseline were performed using 
the ‘metafor’ and ‘metan’ packages in R (version 3.2.1, The R Foundation, Vienna, Austria)17. For all summary 
estimates we specified a random-effects model using the method of DerSimonian and Laird, with the estimate of 
heterogeneity being taken from the inverse-variance fixed-effect model. Between-study heterogeneity was quanti-
fied by the I2 statistic, with sources of heterogeneity explored through subgroup comparisons or meta-regression. 
Bias relating to study effect was assessed with funnel plots and Egger’s asymmetry test18.
Subgroup comparisons. For each of the outcomes, a range of subgroup comparisons were under-
taken. Pre-specified subgroup comparisons included treatment related factors including use of a rush phase, 
co-treatment with additional study medication (e.g. omalizumab), and blinding to treatment allocation. Following 
the publication of a recent meta-analysis on POIT12 we added additional subgroup comparisons including the tar-
get maintenance dose, and use of entry oral food challenge (OFC) to determine eligibility. Further, patient related 
factors included child age, baseline peanut specific IgE (psIgE) and Skin Prick Test (SPT) values, and proportion 
of children with co-morbidities such as asthma, allergic rhinitis, eczema, or other food allergies.
Results
Study search. A total of 2694 titles were identified, which led to 33 articles being analysed for full-text review 
(S1 Figure). After full-text review, 27 published studies involving 1,488 children receiving POIT met the inclusion 
criteria19–45.
included studies. Table 1 details the characteristics of all the studies included in this review. Among the 
27 included studies, 12 (44%) were randomised controlled trials. Of the 12 RCTs, comparator arms included 
randomisation to placebo (n = 6), peanut avoidance (n = 3), sublingual OIT (n = 1), omalizumab (n = 1), or dif-
ferent POIT maintenance doses (n = 1). A co-treatment used in conjunction with POIT was employed by 8 (30%) 
studies (S2 Table). The majority of included studies (n = 20; 74%) incorporated an OFC as part of the eligibility 
criteria. Seventeen (63%) studies incorporated a rush phase as part of their treatment protocol, typically involving 
the rapid escalation of doses over 1-day. The target maintenance dose ranged from 125 mg to 5000 mg peanut 
protein daily. No significant differences in POIT protocols were evident between controlled and non-controlled 
studies (S3 Table).
Substantial heterogeneity was evident with respect to study population (S4 Table). Median age was 8.4 years 
and ranged from 4.8 to 14.5 years. Median psIgE ranged from 9.6 to 229 (median 67.5), while SPT ranged from 
7 to 17.6 (median 11).
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Risk of adverse events resulting in treatment discontinuation. The overall risk of treatment discon-
tinuation due to adverse events was 6.6% (95% CI 4.4–9.0%; I2 = 48.7%; N = 27 studies, Fig. 1), with no evidence 
of publication bias relating to small study effects (p = 0.352, S2 Figure). Risk of treatment discontinuation due to 
adverse events was lower among studies which included co-treatment alongside POIT (1.4%; 0–5.2%) compared 
with studies which used POIT alone (8.5%; 6.5–10.8%; p = 0.003) (Table 2, S3 Figure). When stratified according 
to co-treatment type, a lower risk of treatment discontinuation due to adverse events was noted among studies 

















[UK] No No None None DBPCFC No 0.5 800 Open 22
Anagnostou 2014 
[UK] Yes No Peanut Avoidance None DBPCFC No 2 800 DBPCFC 94
Bird 2015 [USA] No No None None DBPCFC No Variable 2000 DBPCFC 11
Bird 2018 [USA] Yes Yes Placebo None DBPCFC Yes 0.5 to 6 300 DBPCFC 29
Blumchen 2010 
[Germany] No No None None DBPCFC Yes Variable 125 DBPCFC* 23
Blumchen 2019 
[Germany] Yes Yes Placebo None Open No Variable 125 or 250 Open 31
Fauquert 2018 
[France] Yes Yes Placebo None DBPCFC No 2 400 DBPCFC 21
Hofmann 2009 
[USA] No No None None None Yes 0.1 to 50 300 None 28
Howe 2019 [USA] Yes No
Symptoms as side effects 
(n = 24) or symptoms as 
positive signals (n = 26)
Antihistamine None No 1.3 240 None 50
Jones 2009 [USA] No No None None None Yes 0.1 to 50 300 Open 39
Kukkonen 2017 
[Finland] No No Peanut Avoidance Antihistamine DBPCFC No 0.1 800 DBPCFC 39
MacGinnitie 2017 
[USA] Yes No
Omalizumab + Oral OIT 
[n = 27] Vs. Oral OIT alone 
[n = 8]
Omalizumab DBPCFC Yes 0.5 to 250 2000 Open 35
Nachshon 2018 
[Israel] No No None None Open Yes Variable 1200 or 3000 Open 145
Nagakura 2018a 
[Japan] No No None
Antihistamine & 
Montelukast DBPCFC Yes Variable 795 OFC* 22
Nagakura 2018b 
[Japan] No No None Antihistamine Open Yes Variable 133 OFC* 24
Narisety 2015 
[USA] Yes No Oral Vs. Sublingual OIT None Open Yes 0.1 to 6 2000 Open 11
Nozawa 2014 
[Japan] No No None None DBPCFC Yes Variable 1750 or 3500 None 18
PALISADE 2018 
[North America & 
Europe]
Yes Yes Placebo None DBPCFC Yes 0.5 to 6 300 DBPCFC 372
Reier-Nilsen 2019 
[Norway] Yes No Peanut Avoidance None DBPCFC No 5 or 1 5000 None 57
Schneider 2013 
[USA] No No None Omalizumab DBPCFC Yes 0.05 to 250 4000 DBPCFC 13
Tang 2015 
[Australia] Yes Yes Placebo Probiotic
† None Yes 0.1 to 12 2000 DBPCFC 31
Tao 2017 
[Australia] No No None None Open No Boiled 2500 Open 14
Varshney 2011 
[USA] Yes Yes Placebo None None Yes 0.1 to 6 4000 DBPCFC 19
Vickery 2017 
[USA] Yes No
300 mg [n = 20] Vs. 3000 mg 
[17] maintenance dose None Open Yes 0.05 to 3 300 vs. 3000 DBPCFC 37
Wasserman 2019 
[USA] No No None None None Yes
0.001 to 
10 mg/0.002 to 
2.05 mg
3000 None 270
Yu 2012 [USA] No No None None None Yes Variable 4000 None 24
Zhong 2019 
[Singapore] No No None Probiotic
† Open No 0.5 3000 Open 9
Table 1. Characteristics of included peanut oral immunotherapy studies. Abbreviations: RCT, randomised 
controlled trial; OIT, oral immunotherapy; OFC, oral food challenge; DBPCFC, double blind placebo controlled 
food challenge. *OFC completed after 2 weeks of peanut avoidance. †Lactobacillus rhamnosus.
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meta-regression, a higher risk of treatment discontinuation due to adverse events was associated with higher 
baseline peanut specific psIgE (p = 0.0059), and a higher percentage of children with asthma (p = 0.0402) (S5 
Table, S4 Figure).
Adverse events requiring treatment with medications. The overall risk of an adverse event requiring 
treatment was 38.3% (25.1–52.4%; I2 = 79.5%; N = 7 studies, Fig. 2). In subgroup analyses, risk of an adverse 
event requiring treatment was higher among studies which included a rush phase (53.7%; 43.4–63.9) compared 
with studies which commenced with a slow build-up phase (28.1%; 15.7–42.4%; p = 0.005) (Table 3, S5 Figure), 
while frequency of adverse events requiring treatment was lower among studies which included co-treatment 
alongside POIT (9.2 per 10,000 doses; 3.3–17.9) compared with studies which used POIT alone (19.4 per 10,000 
doses; 17.3–21.6; p = 0.027) (S6 Table, S6 Figure). Following univariate meta-regression, increasing median age 
was associated with reduced risk of adverse events requiring treatment (p < 0.001) (S7 Table, S7 Figure), but did 
not appear to influence the frequency (S8 Table, S8 Figure).
The risk of an adverse event requiring treatment was slightly higher across rush (41.5%; 23.1–61.0%: 
I2 = 72.0%, N = 4 studies), and build-up (43.7%; 33.3–54.5%: I2 = 0%, N = 3 studies) treatment phases compared 
with maintenance (20.9%; 9.7–34.7%: I2 = NA%, N = 2 studies) phase (S9 Figure). Similarly, the frequency of an 
Heterogeneity between groups: p = 0.509
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Figure 1. Proportion of participants experiencing adverse events leading to treatment discontinuation.
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adverse event requiring treatment appeared highest during the rush (116.7/1000 doses; 50.7–204.6/1000 doses: 
I2 = 93.9%, N = 4 studies) phase, compared with build-up (31.3/1000 doses; 2.5–88.5/1000 doses: I2 = 99.0%, 
N = 3 studies) and maintenance (18.2/1000 doses; 10.6–27.8/1000 doses: I2 = 97.9%, N = 9 studies) treatment 
phases, but these findings were subject to substantial heterogeneity (S10 Figure).
Adverse events requiring treatment with epinephrine. The overall risk of an adverse event requiring 
treatment with epinephrine was 7.6% (4.5–11.4 I2 = 75.5; N = 26 studies, Fig. 3), while the overall frequency of 
adverse events requiring treatment with epinephrine was 0.20 per 10,000 doses (0.08–0.37; I2 = 64.4%; N = 15 
studies). In subgroup analyses, risk of an adverse event requiring treatment with epinephrine was higher among 
studies which included a rush phase (11.6%; 8.1–15.6%) compared with studies which commenced with a slow 
build-up phase (2.3%; 0.1–6.1%; p = 0.001) and was higher among studies employing a target maintenance dose 
≥1000 mg (13.7%; 9.6–18.3%) compared with <1000 mg (4.0%; 1.1–8.2%; p = 0.001) (Table 3, S11 Figure). 
Similar findings were evident regarding frequency of adverse events requiring treatment with epinephrine (S6 
Table, S12 Figure). Following univariate meta-regression, an increased risk of adverse events requiring treatment 
with epinephrine was associated with increasing median baseline peanut specific IgE (p = 0.0247) (S7 Table, S13 
Figure), while a higher frequency of adverse events requiring treatment with epinephrine was associated with a 
higher target maintenance dose and higher baseline SPT (p = 0.0243) (S8 Table, S14 Figure).
The risk of an adverse event requiring treatment with epinephrine appeared similar across rush (4.1%; 0.7–
9.3%: I2 = 51.3%, N = 9 studies), build-up (3.2%; 0.0–9.5%: I2 = 84.8%, N = 13 studies) and maintenance (3.2%; 
0.9–6.4%: I2 = 53.9%, N = 15 studies) treatment phases (S9 Figure). In contrast, the frequency of an adverse event 
requiring treatment with epinephrine was highest during the rush (2.63/1000 doses; 0.00–11.73/1000 doses: 
I2 = 64.7%, N = 3 studies) treatment phase, compared with build-up (0.00/1000 doses; 0.00–0.20/1000 doses: 
I2 = 0%, N = 7 studies) and maintenance (0.09/1000 doses; 0.00–0.34/1000 doses: I2 = 37.1%, N = 7 studies) treat-
ment phases (S10 Figure).
Likelihood of reaching target maintenance dose. The overall likelihood of reaching target mainte-
nance dose was 80.9% (95% CI 74.2–86.8%; I2 = 86.2%; N = 26 studies, Fig. 4). In subgroup analyses, the pro-
portion reaching target maintenance dose was higher among studies which included co-treatment alongside 
POIT (95.0%; 87.6–99.6%) compared with studies which used POIT alone (72.7%; 64.7–80.0%; p = < 0.001) 
(S9 Table, S15 Figure). When stratified according to co-treatment type, an increased likelihood of reaching the 
target maintenance dose was noted irrespective of the type of co-treatment administered (S9 Table, S15 Figure). 
Following univariate meta-regression, a low likelihood of reaching the target maintenance dose was associated 
with a higher target maintenance dose (p = 0.0088) (S10 Table, S16 Figure).
Comparison Studies % (95% CI) I2 p value
Overall 27 6.6 (4.4–9.0) 48.7 NA
Rush Phase
Yes 17 7.3 (4.7–10.3) 47.2 0.532
No 10 5.3 (1.8–10.1) 50.1
Co-Treatment
  No 20 8.5 (6.5–10.8) 17.7 0.003
  Yes 8 1.4 (0–5.2) 39.5
   Antihistamine Alone 3 10.3 (4.1–23.6) NA
   Antihistamine + Montelukast 1 0.0 (0.0–14.9) NA
   Omalizumab 2 7.2 (0.5–14.9) NA
   Probiotic 3 0.0 (0.0–3.9) NA
Maintenance Dose (mg/day)
<1000 14 5.6 (2.8–9.1) 53.8 0.328
≥1000 12 7.7 (4.1–12.1) 50.4
Entry OFC
DBPCFC 13 9.2 (6.8–12.0) 7.8 0.086
Open 7 3.8 (0.7–8.4) 31.9
None 7 4.8 (0.9–10.8) 71.6
Baseline psIgE (kU/L)
<60 10 2.2 (0.2–5.7) 41.0 <0.001
≥60 14 10.0 (7.8–12.5) 0.00
Baseline SPT (mm)
<12 11 7.7 (5.1–10.7) 36.9 0.422
≥12 9 4.0 (0.3–10.0) 46.3
Table 2. Proportion of participants experiencing adverse events leading to treatment discontinuation according 
to study level characteristics. Abbreviations: psIgE, peanut specific IgE; SPT, skin prick test; NA, not applicable.
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Likelihood of passing supervised exit ofc. The overall likelihood of reaching the end of the study and 
passing a supervised exit oral food challenge was 68.9% (63.5–74.1%; I2 = 53.0%; N = 17 studies, Fig. 5). In sub-
group analyses, the likelihood of passing a supervised food challenge was higher among studies which included 
co-treatment alongside POIT (78.7%; 68.8–87.3%) compared with studies which used POIT alone (65.6%; 58.5–
72.3%; p = 0.035, S9 Table, S17 Figure). When stratified according to co-treatment type, an increased likelihood 
of passing a supervised food challenge was noted among studies that administered probiotics or omalizumab, but 
not antihistamines (S9 Table, S17 Figure). Following univariate meta-regression, a higher likelihood of passing 
a supervised food challenge was associated with higher baseline SPT (p = 0.0058) (S10 Table, S18 Figure). In a 
sensitivity per-protocol analysis, the overall likelihood of passing a supervised oral food challenge and the end 
of POIT treatment among those able to tolerate the maintenance dose was 88.8% (83.2–93.5%; I2 = 68.2) (S19 
Figure).
Discussion
This systematic review and meta-analysis of almost 1,500 peanut allergic patients who received POIT among 
27 controlled and non-controlled studies quantifies the risk and frequency of serious adverse events associated 
with treatment. While POIT appears effective in achieving the immunological goal of desensitisation in large 
proportion of subjects, serious adverse events lead to treatment failure in 1 in 15 subjects. Further, potentially 
life-threatening reactions requiring treatment with epinephrine are experienced by approximately 1 in 13 subjects 
throughout all stages of treatment. While the risk of potentially life-threatening reactions appeared similar across 
treatment phases, the frequency of epinephrine use was low once subjects reached the long-term treatment phase. 
Most notably, we identified modifiable treatment protocol related factors such as the elimination of a rush phase, 
aiming for a lower target maintenance dose, or use of co-treatments in addition to POIT, that could substantially 
improve the safety and efficacy of treatment regimens and warrant evaluation in future clinical trials.
Our study findings significantly expand upon those of the recent meta-analysis published by Chu et al.12, 
through including an additional 15 studies and data on more than twice the number of participants receiving 
POIT. Despite differences in inclusion of controlled and non-controlled studies, Chu et al. observed an absolute 
risk of adverse events resulting in treatment discontinuation of 6.1% (2.9–12.9) compared to our observed risk 
of 6.6% (4.4–9.0%). Similarly, our observed risk of epinephrine use of 7.6% (4.5–11.4%) was similar to the risk of 
8.2% (4.7–14.2%) reported by Chu et al. A major point of difference to the previous meta-analysis by Chu et al. 
was the extraction of data pertaining to the frequency of adverse events. Examination of these data revealed that, 
while the risk of serious adverse events to POIT may appear high at up to 39.4%, the frequency with which they 
occur is quite low, with 11.3 per 1,000 doses (5.4–19.5) resulting in adverse events requiring medication ther-
apy and 0.2 per 1,000 doses (0.08–0.37) resulting in epinephrine use. Lastly, in their summary of findings table 
Chu et al. report an observed anticipated absolute treatment effect of passing a supervised exit OFC following 
Heterogeneity between groups: p = 0.651
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Figure 2. Proportion of participants experiencing adverse events requiring treatment.
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POIT of 39.7% (21.8–72.3%), based on the corresponding risk ratio of 12.42 (6.82–22.61) generated from their 
meta-analysis12. This substantially differs from the reported prevalence of passing a supervised exit OFC follow-
ing POIT of 56% (n = 320/574)12, based on the crude data included in their-meta-analysis. A second issue is their 
inclusion of an unpublished study (NCT01324401 [PNOIT]; 2018) that performed the exit OFC one month after 
treatment avoidance. This study provided the lowest risk estimate for passing a supervised exit OFC (RR 3.30; 
0.60–18.23) and therefore lowered the overall risk estimate, but was not eligible for inclusion as it was evaluating 
sustained unresponsiveness. In contrast, our meta-analysis demonstrated a higher overall pooled likelihood of 
passing a supervised exit OFC of 69.1% (58.1–79.1%) among blinded RCTs and 68.9% (62.1–75.4%) among 
open-label studies. Determining the true expected treatment effect should be the focus of future studies as this is 
likely to be a key factor influencing decision making regarding POIT.
Despite investigating more than 10 study-level factors in sub-group analyses, Chu et al. identified that only the 
requirement for failing an entry OFC as an entry criterion was associated with an increased risk of anaphylaxis 
during POIT12. The inability to detect additional associations is likely the result of inadequate statistical power. 
This is in contrast to the novel findings of our meta-analysis where use of an initial rush phase was consistently 
associated with an increased risk of serious adverse events, while aiming for a higher target maintenance dose 
was associated with an increased risk for epinephrine use. Further, use of co-treatment in addition to POIT was 
associated with a reduction in adverse events resulting in treatment discontinuation.
Only three RCTs have been undertaken to examine the effects of different approaches to POIT. These include 
different target maintenance doses (300 mg or 3000 mg peanut protein daily)42, use of co-treatment (omalizumab 
vs. placebo)30, or changing psychological mindset regarding symptoms associated with POIT27. While these 
studies, which recruiting between 35 to 50 patients, provided some promising evidence that targeting a lower 
target maintenance dose, utilising a co-treatment, or providing a psychological intervention may reduce the risk 
and frequency of adverse events, they were insufficiently powered to detect any clinically significant differences. 
Notably, we were able to overcome this limitation of relying on single studies by pooling data across studies in the 
largest meta-analysis undertaken on POIT to date.
Few previous studies have attempted to evaluate patient-level factors associated with the risk of adverse events 
during POIT, including three trials using individual patient data37,43,46 and one meta-analysis12. Two studies 
examined differences in patient characteristics according to frequency of overall adverse events or epinephrine 
use43,46. Findings have been largely inconsistent, with one study demonstrating that rhinitis, asthma, and base-
line SPT were all associated with an increased risk of adverse events46, while the other demonstrated that higher 
baseline psIgE was associated with an increased risk of epinephrine use43. In the meta-analysis by Chu et al., only 
increasing age was associated with an increased risk of serious adverse events12. We observed an increased risk of 
Comparison
Risk of Adverse Event Requiring Treatment Risk of Adverse Event Requiring Epinephrine
Studies % (95% CI) I2 p value Studies % (95% CI) I2 p value
Overall
7 38.3 (25.1–52.4) 79.5 NA 26 7.6 (4.5–11.4) 75.5 NA
Rush Phase
Yes 3 53.7 (43.4–63.9) NA 0.005 17 11.6 (8.1–15.6) 57.8 0.001
No 4 28.1 (15.7–42.4) 68.9 9 2.3 (0.1–6.1) 53.2
Co-Treatment
Yes 1 41 (27.1–56.6) NA NA 7 6.6 (1.9–13.2) 52.7 0.677
No 6 37.8 (22.4–54.5) 82.6 20 8.0 (4.3–12.5) 77.4
Intervention Blinding
Yes 2 41.9 (28.3–56.2) NA 0.651 6 7.3 (2.5–13.7) 59.4 0.825
No 5 36.7 (19.8–55.4) 85.6 20 7.9 (3.9–12.8) 78.8
Maintenance Dose (mg/day)
<1000 5 40.5 (24.6–57.5) 82.7 0.880 13 4.0 (1.1–8.2) 74.8 0.001
≥1000 3 38.0 (16.2–62.3) NA 14 13.7 (9.6–18.3) 37.7
Entry OFC
DBPCFC 2 24.9 (17.8–32.8) NA 0.001 13 6.8 (3.2–11.4) 63.7 0.784
Open 3 37.1 (17.7–58.6) NA 6 6.1 (0.2–16.7) 79.1
None 2 53.5 (40.3–66.5) NA 7 10.3 (3.2–20.2) 82.8
Baseline psIgE (kU/L)
<60 3 28.6 (7.9–55.1) NA 0.215 10 2.8 (0.4–6.5) 43.7 0.018
≥60 4 46.1 (37.3–55.0) 0 14 9.1 (5.7–13.2) 46.0
Baseline SPT (mm)
<12 5 38.6 (24.0–54.2) 79.2 NA 11 7.1 (3.3–12.1) 76.4 0.548
≥12 1 14.3 (4.0–39.9) NA 8 8.3 (3.3–14.9) 31.4
Table 3. Risk of different types of adverse events according to study characteristics. Abbreviations: OFC, oral 
food challenge; DBPCFC, double blind placebo controlled food challenge; psIgE, peanut specific IgE; SPT, skin 
prick test.
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adverse events among studies with a higher proportion of participants with rhinitis, while a higher proportion of 
participants with eczema and higher median age were associated with increased risk of adverse events requiring 
treatment. Further, our meta-analysis provides evidence suggesting that both higher baseline psIgE and SPT may 
increase the risk of adverse events during POIT, but each of these findings requires clarification in further studies.
Strengths of our meta-analysis include the thorough literature search, inclusion of data from controlled and 
non-controlled studies, and use of appropriate statistical methods for pooling prevalence data and undertaking 
meta-regression analyses. Our study also has some limitations. Because this is a study-level analysis, it is not pos-
sible to make inferences regarding which individual patients are at higher risk of adverse events related to POIT. 
Confidence intervals for pooling risk estimates include both between-study and within-study variations, and 
should be interpreted cautiously. Future studies pooling individual patient data could overcome such limitations. 
A high level of heterogeneity was observed across some study outcomes, which we attempted to take into account 
using random effects models, and explored through performing subgroup comparisons. An additional limitation 
was the incomplete reporting of data on some outcomes or study-level characteristics across studies. For example, 
less than half of included studies separated adverse event data according to treatment phase. Further, definitions 
of adverse events varied across studies. Some studies reported adverse events regardless of severity, while others 
restricted reporting to those considered to be moderate or severe. Greater efforts should be made to standardise 
reporting of adverse events in future clinical trials to facilitate pooling of data. Lastly, in some situations the study 
protocol was modified part way during the study31,35,43, with outcomes data reported for participants overall, 
rather than separated according to use of different treatment protocols.
Heterogeneity between groups: p = 0.825
Overall  (I^2 = 75.5%, p = 0.0);
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Figure 3. Proportion of participants experiencing adverse events requiring treatment with epinephrine.
9Scientific RepoRtS |          (2020) 10:659  | https://doi.org/10.1038/s41598-019-56961-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
While the risk of severe adverse reactions requiring treatment with epinephrine might appear high at 7.6%, 
this must be balanced against the benefits of POIT in providing protection against accidental peanut ingestion. A 
longitudinal study of a population of children who had developed peanut allergy before the age of 4 years revealed 
that, of the children with initial non-life-threatening reactions, 44% had at least one potentially life-threatening 
reaction during follow-up47. Based on this meta-analysis, once children reached the long-term maintenance 
phase of POIT, the risk of experiencing a significant adverse event requiring treatment with epinephrine was 
3.2%, while the frequency was extremely low at 9 episodes per 100,000 doses.
Our findings are novel and identify modifiable study protocol related factors that can guide development 
of future treatment protocols that are safer and more effective. Given the current evidence that OIT is superior 
to placebo in achieving the immunological goal of desensitisation, future clinical trials should be focused on 
improving treatment protocols with the aim of improving safety, while maintaining high levels of efficacy. While 
expense and administration-related challenges associated with the use of omalizumab as a co-treatment may 
prohibit widespread adoption in clinical practice, we observed evidence that lower cost co-treatments such as use 
of oral antihistamines or probiotics were also associated with improved treatment-related outcomes. The specific 
value of these co-treatments should be evaluated in appropriate clinical trials. Further, in situations where POIT 
is currently offered to patients, our study provides significant information regarding not only the risk, but also 
frequency, of adverse events and related outcomes.
Lastly, an interesting observation relating to various treatment protocols was the inclusion of various rec-
ommendations made regarding dosing restrictions aiming to minimise the risk of potential adverse events. For 
example, some studies recommend avoiding exercise within 3 hours of dosing36, avoiding a hot shower or bath 
Heterogeneity between groups: p = 0.687
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Figure 4. Proportion of participants able to reach target maintenance dose.
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for up to 4 hours following dosing22, or avoiding dosing during episodes of illness such as respiratory infections41, 
or during menstruation22. Notably, no studies evaluated patient adherence to such treatment recommendations. 
Further, reporting of potential attenuating risk factors at the time of adverse event occurrence is very limited 
and inconsistent across studies. This means that based on included studies it is not possible to evaluate whether 
adherence to such treatment recommendations actually alters treatment outcomes. Given the lack of high-quality 
data regarding the relationship between such factors and the occurrence of adverse events, as well as underlying 
biological mechanisms, such recommendations should be the focus of future research.
In conclusion, while the majority of children undergoing POIT are able to be effectively desensitised and are 
protected from accidental peanut ingestion, this study provides promising evidence that certain modifications to 
existing treatment protocols could significantly improve treatment safety and efficacy. In particular, modifications 
to POIT treatment protocols, such as the avoidance of a rush phase, lower target maintenance doses, or use of 
co-treatments, warrant appropriate evaluation in future clinical trials, as well as further studies identifying those 
at greatest risk of experiencing serious adverse events.
Data availability
All data generated and analysed during the study are included in this published article.
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Figure 5. Proportion of participants able to complete peanut oral immunotherapy and pass supervised exit oral 
food challenge.
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